115 related articles for article (PubMed ID: 17465714)
1. Pharmacogenetics and stomach cancer: an update.
Toffoli G; Cecchin E
Pharmacogenomics; 2007 May; 8(5):497-505. PubMed ID: 17465714
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and stomach cancer.
Toffoli G; Cecchin E
Pharmacogenomics; 2004 Sep; 5(6):627-41. PubMed ID: 15335285
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases.
Wolschke C; Goekkurt E; Al-Batran SE; Hossfeld DK; Stoehlmacher J
Onkologie; 2005 Nov; 28(11):589-92. PubMed ID: 16249645
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer pharmacogenetics: progress or old tripe?
Patel JN; Fuchs CS; Owzar K; Chen Z; McLeod HL
Pharmacogenomics; 2013 Jul; 14(9):1053-64. PubMed ID: 23837480
[TBL] [Abstract][Full Text] [Related]
7. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
[TBL] [Abstract][Full Text] [Related]
8. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Ruzzo A; Graziano F; Kawakami K; Watanabe G; Santini D; Catalano V; Bisonni R; Canestrari E; Ficarelli R; Menichetti ET; Mari D; Testa E; Silva R; Vincenzi B; Giordani P; Cascinu S; Giustini L; Tonini G; Magnani M
J Clin Oncol; 2006 Apr; 24(12):1883-91. PubMed ID: 16622263
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy.
Nishiyama M; Eguchi H
Adv Drug Deliv Rev; 2009 May; 61(5):402-7. PubMed ID: 19133303
[TBL] [Abstract][Full Text] [Related]
11. Update on pharmacogenetics in cancer chemotherapy.
Innocenti F; Ratain MJ
Eur J Cancer; 2002 Mar; 38(5):639-44. PubMed ID: 11916544
[TBL] [Abstract][Full Text] [Related]
12. Determinants of chemosensitivity in gastric cancer.
Park DJ; Lenz HJ
Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
[TBL] [Abstract][Full Text] [Related]
13. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
15. Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics.
Lima A; Azevedo R; Sousa H; Seabra V; Medeiros R
Pharmacogenomics; 2013 Aug; 14(11):1337-51. PubMed ID: 23930679
[TBL] [Abstract][Full Text] [Related]
16. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
